Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Tempo brings in $8mm through Series B round

Executive Summary

Tempo Pharmaceuticals (nanoparticle-based drug delivery platform) raised $8mm through its Series B round. Existing investors Polaris Venture Partners, Venrock, and Lux Capital were joined by new buyers Bessemer Venture Partners, Alexandria Real Estate Equities, and an individual investor from Venrock.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
  • Biotechnology
    • Nanotechnology, Chips, etc.
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies